Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ETNB 89bio Inc
- Stocks
- Healthcare
- NASDAQ: ETNB
Price (delayed)
$10
Market cap
$1.46B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.41
Enterprise value
$1.18B
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is
Highlights
The equity has soared by 51% since the previous quarter and by 19% year-on-year
89bio's quick ratio has increased by 38% from the previous quarter and by 15% YoY
ETNB's EPS has dropped by 70% year-on-year but it is up by 2.8% since the previous quarter
The company's net income has shrunk by 134% YoY and by 5% QoQ
89bio's debt has increased by 38% YoY
Key stats
What are the main financial stats of ETNB
Market
Valuations
Earnings
Shares outstanding
145.98M
Market cap
$1.46B
Enterprise value
$1.18B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.41
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$403.29M
Net income
-$386.67M
EBIT
-$380.25M
EBITDA
-$379.5M
Free cash flow
-$399.93M
Per share
Balance sheet
Liquidity
EPS
-$3.41
EPS diluted
-$3.41
Free cash flow per share
-$2.73
Book value per share
$4.15
Revenue per share
$0
TBVPS
$4.68
Total assets
$685.03M
Total liabilities
$79.57M
Debt
$37.58M
Equity
$605.46M
Working capital
$645.06M
Debt to equity
0.06
Current ratio
18.03
Quick ratio
16.86
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-70.2%
Return on equity
-81.4%
Return on invested capital
-105.3%
Return on capital employed
-58.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ETNB stock price
How has the 89bio stock price performed over time
Intraday
0.6%
1 week
-0.4%
1 month
28.62%
1 year
19.05%
YTD
27.88%
QTD
37.55%
Financial performance
How have 89bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$403.29M
Net income
-$386.67M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 134% YoY and by 5% QoQ
The company's operating income has shrunk by 124% YoY and by 4.8% QoQ
Price vs fundamentals
How does ETNB's price correlate with its fundamentals
Growth
What is 89bio's growth rate over time
Valuation
What is 89bio stock price valuation
P/E
N/A
P/B
2.41
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ETNB's EPS has dropped by 70% year-on-year but it is up by 2.8% since the previous quarter
The equity has soared by 51% since the previous quarter and by 19% year-on-year
The stock's price to book (P/B) is 26% more than its last 4 quarters average of 1.9 and 9% more than its 5-year quarterly average of 2.2
Efficiency
How efficient is 89bio business performance
89bio's return on equity has shrunk by 134% YoY
ETNB's return on assets has dropped by 126% year-on-year
The ROIC has plunged by 81% YoY and by 3.8% from the previous quarter
Dividends
What is ETNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ETNB.
Financial health
How did 89bio financials performed over time
ETNB's total assets is up by 43% since the previous quarter and by 19% year-on-year
89bio's quick ratio has increased by 38% from the previous quarter and by 15% YoY
89bio's debt is 94% lower than its equity
The equity has soared by 51% since the previous quarter and by 19% year-on-year
89bio's debt has increased by 38% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.